Luca Gianni, MD, on the Neoadjuvant Treatment of Triple-Negative Breast Cancer
2019 San Antonio Breast Cancer SymposiumLuca Gianni, MD, of the Fondazione Michelangelo, discusses findings from the NeoTRIP trial on pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk, and locally advanced breast cancer (Abstract GS3-04).
Related Videos
Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine
Miguel Martín, MD, PhD, of the Gregorio Marañón Institute and GEICAM, discusses phase III study findings that showed no improvement in progression-free survival with palbocic...
Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
Ivana Sestak, PhD, of Queen Mary University of London and the Centre for Cancer Prevention, discusses study findings that confirm the prognostic ability of the Clinical Treat...
Ian E. Krop, MD, PhD, on Trastuzumab Deruxtecan for Patients With Previously Treated, HER2-Positive Metastatic Breast Cancer
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses phase II trial findings on trastuzumab deruxtecan, a HER2-targeting antibody-drug conjugate, in patients with...
Gerardo Antonio Umanzor Funez, MD, on Metastatic Breast Cancer: Comparing IV and Oral Formulations of Paclitaxel
Gerardo Antonio Umanzor Funez, MD, of Liga Contra El Cáncer, discusses phase III findings on intravenous (IV) paclitaxel and oral paclitaxel plus encequidar (a novel P-gp inh...
Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer
Milan Radovich, PhD, of Indiana University School of Medicine, discusses trial findings that show patients with triple-negative breast cancer who are at high risk of relapse ...
